Marksans Pharma Limited
Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, uppe… Read more
Marksans Pharma Limited (MARKSANS) - Net Assets
Latest net assets as of September 2025: ₹27.14 Billion INR
Based on the latest financial reports, Marksans Pharma Limited (MARKSANS) has net assets worth ₹27.14 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹34.42 Billion) and total liabilities (₹7.28 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹27.14 Billion |
| % of Total Assets | 78.84% |
| Annual Growth Rate | 17.3% |
| 5-Year Change | 174.96% |
| 10-Year Change | 438.03% |
| Growth Volatility | 69.98 |
Marksans Pharma Limited - Net Assets Trend (2005–2025)
This chart illustrates how Marksans Pharma Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Marksans Pharma Limited (2005–2025)
The table below shows the annual net assets of Marksans Pharma Limited from 2005 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹24.89 Billion | +19.34% |
| 2024-03-31 | ₹20.86 Billion | +18.18% |
| 2023-03-31 | ₹17.65 Billion | +44.33% |
| 2022-03-31 | ₹12.23 Billion | +35.08% |
| 2021-03-31 | ₹9.05 Billion | +39.47% |
| 2020-03-31 | ₹6.49 Billion | +17.45% |
| 2019-03-31 | ₹5.53 Billion | +15.05% |
| 2018-03-31 | ₹4.80 Billion | +6.56% |
| 2017-03-31 | ₹4.51 Billion | -2.56% |
| 2016-03-31 | ₹4.63 Billion | +19.29% |
| 2015-03-31 | ₹3.88 Billion | +160.63% |
| 2014-03-31 | ₹1.49 Billion | +59.22% |
| 2013-03-31 | ₹934.69 Million | +157.53% |
| 2012-03-31 | ₹-1.62 Billion | -241.32% |
| 2011-03-31 | ₹1.15 Billion | -29.04% |
| 2010-03-31 | ₹1.62 Billion | +7.31% |
| 2009-03-31 | ₹1.51 Billion | +6.23% |
| 2008-03-31 | ₹1.42 Billion | +12.45% |
| 2007-03-31 | ₹1.26 Billion | +5.64% |
| 2006-03-31 | ₹1.20 Billion | +16.94% |
| 2005-03-31 | ₹1.02 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Marksans Pharma Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 7181.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹14.22 Billion | 57.64% |
| Common Stock | ₹453.16 Million | 1.84% |
| Other Comprehensive Income | ₹4.95 Billion | 20.07% |
| Other Components | ₹5.04 Billion | 20.45% |
| Total Equity | ₹24.67 Billion | 100.00% |
Marksans Pharma Limited Competitors by Market Cap
The table below lists competitors of Marksans Pharma Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Cisarua Mountain Dairy Tbk PT
JK:CMRY
|
$428.70 Million |
|
Chin-Poon Industrial Co Ltd
TW:2355
|
$428.70 Million |
|
Guangdong Kinlong Hardware Products Co Ltd
SHE:002791
|
$428.75 Million |
|
New Trend International Logis-Tech Co Ltd
SHE:300532
|
$428.82 Million |
|
Great-Sun Foods Co Ltd
SHG:603336
|
$428.52 Million |
|
Liaoning Shenhua Holdings Co Ltd
SHG:600653
|
$428.45 Million |
|
VISHAY PREC GRP
MU:SV5
|
$428.31 Million |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
|
$428.23 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Marksans Pharma Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 20,650,540,000 to 24,669,120,000, a change of 4,018,580,000 (19.5%).
- Net income of 3,805,750,000 contributed positively to equity growth.
- Dividend payments of 271,900,000 reduced retained earnings.
- Other comprehensive income increased equity by 487,740,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹3.81 Billion | +15.43% |
| Dividends Paid | ₹271.90 Million | -1.1% |
| Other Comprehensive Income | ₹487.74 Million | +1.98% |
| Other Changes | ₹-3.01 Million | -0.01% |
| Total Change | ₹- | 19.46% |
Book Value vs Market Value Analysis
This analysis compares Marksans Pharma Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.18x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 69.29x to 3.18x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-03-31 | ₹2.50 | ₹173.18 | x |
| 2006-03-31 | ₹3.33 | ₹173.18 | x |
| 2007-03-31 | ₹3.60 | ₹173.18 | x |
| 2008-03-31 | ₹3.86 | ₹173.18 | x |
| 2009-03-31 | ₹4.13 | ₹173.18 | x |
| 2010-03-31 | ₹4.38 | ₹173.18 | x |
| 2011-03-31 | ₹3.06 | ₹173.18 | x |
| 2012-03-31 | ₹-4.36 | ₹173.18 | x |
| 2013-03-31 | ₹2.24 | ₹173.18 | x |
| 2014-03-31 | ₹3.69 | ₹173.18 | x |
| 2015-03-31 | ₹9.28 | ₹173.18 | x |
| 2016-03-31 | ₹11.10 | ₹173.18 | x |
| 2017-03-31 | ₹10.86 | ₹173.18 | x |
| 2018-03-31 | ₹11.50 | ₹173.18 | x |
| 2019-03-31 | ₹13.25 | ₹173.18 | x |
| 2020-03-31 | ₹15.54 | ₹173.18 | x |
| 2021-03-31 | ₹21.66 | ₹173.18 | x |
| 2022-03-31 | ₹29.37 | ₹173.18 | x |
| 2023-03-31 | ₹42.01 | ₹173.18 | x |
| 2024-03-31 | ₹45.57 | ₹173.18 | x |
| 2025-03-31 | ₹54.45 | ₹173.18 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Marksans Pharma Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 15.43%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 14.51%
- • Asset Turnover: 0.81x
- • Equity Multiplier: 1.31x
- Recent ROE (15.43%) is above the historical average (6.00%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 20.10% | 8.13% | 1.08x | 2.30x | ₹103.28 Million |
| 2006 | 19.13% | 7.70% | 0.64x | 3.90x | ₹109.28 Million |
| 2007 | 5.29% | 2.77% | 0.49x | 3.88x | ₹-59.49 Million |
| 2008 | 11.08% | 5.96% | 0.48x | 3.89x | ₹15.34 Million |
| 2009 | -5.56% | -2.32% | 0.57x | 4.19x | ₹-233.84 Million |
| 2010 | -6.23% | -2.79% | 0.56x | 4.01x | ₹-261.53 Million |
| 2011 | -198.54% | -73.12% | 0.47x | 5.81x | ₹-2.34 Billion |
| 2012 | 0.00% | -50.30% | 0.92x | 0.00x | ₹-1.62 Billion |
| 2013 | 53.06% | 10.47% | 1.09x | 4.64x | ₹372.36 Million |
| 2014 | 50.57% | 11.41% | 1.29x | 3.45x | ₹576.89 Million |
| 2015 | 28.81% | 13.73% | 1.18x | 1.78x | ₹714.20 Million |
| 2016 | 17.28% | 8.79% | 1.24x | 1.59x | ₹330.79 Million |
| 2017 | 2.14% | 1.24% | 1.02x | 1.69x | ₹-349.39 Million |
| 2018 | 7.00% | 3.61% | 1.25x | 1.55x | ₹-141.46 Million |
| 2019 | 14.83% | 8.15% | 1.23x | 1.48x | ₹261.89 Million |
| 2020 | 18.99% | 10.69% | 1.26x | 1.41x | ₹571.51 Million |
| 2021 | 26.91% | 17.43% | 1.11x | 1.39x | ₹1.50 Billion |
| 2022 | 15.35% | 12.47% | 0.90x | 1.36x | ₹643.42 Million |
| 2023 | 15.26% | 14.38% | 0.85x | 1.26x | ₹917.92 Million |
| 2024 | 15.19% | 14.41% | 0.81x | 1.30x | ₹1.07 Billion |
| 2025 | 15.43% | 14.51% | 0.81x | 1.31x | ₹1.34 Billion |
Industry Comparison
This section compares Marksans Pharma Limited's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $5,549,619,840
- Average return on equity (ROE) among peers: 23.13%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Marksans Pharma Limited (MARKSANS) | ₹27.14 Billion | 20.10% | 0.27x | $428.52 Million |
| GlaxoSmithKline Pharmaceuticals Limited (GLAXO) | $16.96 Billion | 22.18% | 0.80x | $1.19 Billion |
| Kopran Limited (KOPRAN) | $1.09 Billion | 9.86% | 1.43x | $34.19 Million |
| NGL Fine-Chem Limited (NGLFINE) | $160.59 Million | 15.04% | 1.05x | $39.88 Million |
| Pfizer Limited (PFIZER) | $9.01 Billion | 33.25% | 0.22x | $818.67 Million |
| Sanofi India Limited (SANOFI) | $17.36 Billion | 17.53% | 0.46x | $376.73 Million |
| SANOFI CONS HEALTHC IND L (SANOFICONR) | $2.08 Billion | 79.43% | 0.66x | $324.08 Million |
| SENORES PHARMACEUTICALS L (SENORES) | $94.96 Million | 7.21% | 0.53x | $157.65 Million |
| SMS Pharmaceuticals Limited (SMSPHARMA) | $2.22 Billion | 9.19% | 1.30x | $105.56 Million |
| TTK Healthcare Limited (TTKHLTCARE) | $982.22 Million | 14.46% | 1.13x | $31.85 Million |